Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|68|4-6|438-445

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.4-6, 2005-08, pp. : 438-445

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 197-203

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 250-256

Karger

Access to resources Recommend Favorite

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 5, 2007-01 ,pp. : 330-338

Karger

Access to resources Recommend Favorite